{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:47:52Z","timestamp":1793832472420,"version":"4.6.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T00:00:00Z","timestamp":1615420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T00:00:00Z","timestamp":1615420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinik M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The aim of this prospective study is to evaluate the clinical use and real-world efficacy of durvalumab maintenance treatment after chemoradiotherapy (CRT) in unresectable stage, locally advanced non-small cell lung cancer (NSCLC). All consecutive patients with unresectable, locally advanced NSCLC and PD-L1 expression (\u22651%) treated after October 2018 were included. Regular follow up, including physical examination, PET\/CT and\/or contrast-enhanced CT-Thorax\/Abdomen were performed every three months after CRT. Descriptive treatment pattern analyses, including reasons of discontinuation and salvage treatment, were undertaken. Statistics were calculated from the last day of thoracic irradiation (TRT). Twenty-six patients were included. Median follow up achieved 20.6\u00a0months (range: 1.9\u201330.6). Durvalumab was initiated after a median of 25 (range: 13\u2013103) days after completion of CRT. In median 14 (range: 2\u201324) cycles of durvalumab were applied within 6.4 (range 1\u201312.7) months. Six patients (23%) are still in treatment and seven (27%) have completed treatment with 24\u00a0cycles. Maintenance treatment was discontinued in 13 (50%) patients: 4 (15%) patients developed grade 3 pneumonitis according to CTCAE v5 after a median of 3.9 (range: 0.5\u201311.6) months and 7 (range: 2\u201317) cycles of durvalumab. Four (15%) patients developed grade 2 skin toxicity. One (4%) patient has discontinued treatment due to incompliance. Six and 12- month progression-free survival (PFS) rates were 82% and 62%, median PFS was not reached. No case of hyperprogression was documented. Eight (31%) patients have relapsed during maintenance treatment after a median of 4.8 (range: 2.2\u201311.3) months and 11 (range: 6\u201317) durvalumab cycles. Two patients (9%) developed a local-regional recurrence after 14 and 17\u00a0cycles of durvalumab. Extracranial distant metastases and brain metastases as first site of failure were detected in 4 (15%) and 2 (8%) patients, respectively. Three (13%) patients presented with symptomatic relapse. Our prospective study confirmed a favourable safety profile of durvalumab maintenance treatment after completion of CRT in unresectable stage, locally advanced NSCLC in a real-world setting. In a median follow-up time of 20.6\u00a0months, durvalumab was discontinued in 27% of all patients due to progressive disease. All patients with progressive disease were eligible for second-line treatment.<\/jats:p>","DOI":"10.1007\/s10637-021-01091-9","type":"journal-article","created":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T13:02:55Z","timestamp":1615467775000},"page":"1189-1196","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients"],"prefix":"10.1007","volume":"39","author":[{"given":"Julian","family":"Taugner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6260-5249","authenticated-orcid":false,"given":"Lukas","family":"K\u00e4smann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chukwuka","family":"Eze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"R\u00fchle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Tufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Reinmuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Duell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Belka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farkhad","family":"Manapov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,11]]},"reference":[{"key":"1091_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA A Cancer J Clin 69:7\u201334. https:\/\/doi.org\/10.3322\/caac.21551","journal-title":"CA A Cancer J Clin"},{"key":"1091_CR2","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13014-020-01590-8","volume":"15","author":"J Taugner","year":"2020","unstructured":"Taugner J, Eze C, K\u00e4smann L, Roengvoraphoj O, Gennen K, Karin M, Petrukhnov O, Tufman A, Belka C, Manapov F (2020) Pattern-of-failure and salvage treatment analysis after chemoradiotherapy for inoperable stage III non-small cell lung cancer. Radiat Oncol 15:148. https:\/\/doi.org\/10.1186\/s13014-020-01590-8","journal-title":"Radiat Oncol"},{"key":"1091_CR3","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/bjc.2017.232","volume":"117","author":"M Alexander","year":"2017","unstructured":"Alexander M, Wolfe R, Ball D, Conron M, Stirling RG, Solomon B, MacManus M, Officer A, Karnam S, Burbury K, Evans SM (2017) Lung cancer prognostic index: a risk score to predict overall survival after the diagnosis of non-small-cell lung cancer. Br J Cancer 117:744\u2013751. https:\/\/doi.org\/10.1038\/bjc.2017.232","journal-title":"Br J Cancer"},{"key":"1091_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5306\/wjco.v8.i1.1","volume":"8","author":"SM Yoon","year":"2017","unstructured":"Yoon SM, Shaikh T, Hallman M (2017) Therapeutic management options for stage III non-small cell lung cancer. World J Clin Oncol 8:1\u201320. https:\/\/doi.org\/10.5306\/wjco.v8.i1.1","journal-title":"World J Clin Oncol"},{"key":"1091_CR5","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1093\/jnci\/88.17.1210","volume":"88","author":"RO Dillman","year":"1996","unstructured":"Dillman RO, Herndon J, Seagren SL, Eaton WL, Green MR (1996) Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 88:1210\u20131215. https:\/\/doi.org\/10.1093\/jnci\/88.17.1210","journal-title":"J Natl Cancer Inst"},{"key":"1091_CR6","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1097\/JTO.0b013e3182429682","volume":"7","author":"M Machtay","year":"2012","unstructured":"Machtay M, Paulus R, Moughan J, Komaki R, Bradley JE, Choy H, Albain K, Movsas B, Sause WT, Curran WJ (2012) Defining local-regional control and its importance in locally advanced non-small cell lung carcinoma. J Thorac Oncol 7:716\u2013722. https:\/\/doi.org\/10.1097\/JTO.0b013e3182429682","journal-title":"J Thorac Oncol"},{"key":"1091_CR7","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpe\u00f1o J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, \u00d6zg\u00fcro\u011flu M (2017) Durvalumab after Chemoradiotherapy in stage III non-small-cell lung Cancer. N Engl J Med 377:1919\u20131929. https:\/\/doi.org\/10.1056\/NEJMoa1709937","journal-title":"N Engl J Med"},{"key":"1091_CR8","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","volume":"379","author":"SJ Antonia","year":"2018","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpe\u00f1o J, Faivre-Finn C, Reck M, Vansteenkiste J, Spigel DR, Wadsworth C, Melillo G, Taboada M, Dennis PA, \u00d6zg\u00fcro\u011flu M (2018) Overall survival with Durvalumab after Chemoradiotherapy in stage III NSCLC. N Engl J Med 379:2342\u20132350. https:\/\/doi.org\/10.1056\/NEJMoa1809697","journal-title":"N Engl J Med"},{"key":"1091_CR9","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jtho.2019.10.002","volume":"15","author":"JE Gray","year":"2020","unstructured":"Gray JE, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, Cho BC, Planchard D, Paz-Ares L, Faivre-Finn C, Vansteenkiste JF, Spigel DR, Wadsworth C, Taboada M, Dennis PA, \u00d6zg\u00fcro\u011flu M, Antonia SJ (2020) Three-year overall survival with Durvalumab after Chemoradiotherapy in stage III NSCLC-update from PACIFIC. J Thorac Oncol 15:288\u2013293. https:\/\/doi.org\/10.1016\/j.jtho.2019.10.002","journal-title":"J Thorac Oncol"},{"key":"1091_CR10","doi-asserted-by":"publisher","first-page":"288","DOI":"10.21037\/tlcr.2020.03.25","volume":"9","author":"L K\u00e4smann","year":"2020","unstructured":"K\u00e4smann L, Eze C, Taugner J, Roengvoraphoj O, Belka C, Manapov F (2020) Implementation of durvalumab maintenance treatment after concurrent chemoradiotherapy in inoperable stage III non-small cell lung cancer (NSCLC)-a German radiation oncology survey. Transl. Lung Cancer Res. 9:288\u2013293. https:\/\/doi.org\/10.21037\/tlcr.2020.03.25","journal-title":"Transl. Lung Cancer Res."},{"key":"1091_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.radonc.2018.02.023","volume":"127","author":"U Nestle","year":"2018","unstructured":"Nestle U, de Ruysscher D, Ricardi U, Geets X, Belderbos J, P\u00f6ttgen C, Dziadiuszko R, Peeters S, Lievens Y, Hurkmans C, Slotman B, Ramella S, Faivre-Finn C, McDonald F, Manapov F, Putora PM, LeP\u00e9choux C, van Houtte P (2018) ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer. Radiother Oncol 127:1\u20135. https:\/\/doi.org\/10.1016\/j.radonc.2018.02.023","journal-title":"Radiother Oncol"},{"key":"1091_CR12","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s13014-020-01654-9","volume":"15","author":"L K\u00e4smann","year":"2020","unstructured":"K\u00e4smann L, Dietrich A, Staab-Weijnitz CA, Manapov F, Behr J, Rimner A, Jeremic B, Senan S, de Ruysscher D, Lauber K, Belka C (2020) Radiation-induced lung toxicity - cellular and molecular mechanisms of pathogenesis, management, and literature review. Radiat Oncol 15:214. https:\/\/doi.org\/10.1186\/s13014-020-01654-9","journal-title":"Radiat Oncol"},{"key":"1091_CR13","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00280-019-03885-4","volume":"84","author":"K Hosoya","year":"2019","unstructured":"Hosoya K, Fujimoto D, Kawachi H, Sato Y, Kogo M, Nagata K, Nakagawa A, Tachikawa R, Hiraoka S, Kokubo M, Tomii K (2019) Ineligibility for the PACIFIC trial in unresectable stage III non-small cell lung cancer patients. Cancer Chemother Pharmacol 84:275\u2013280. https:\/\/doi.org\/10.1007\/s00280-019-03885-4","journal-title":"Cancer Chemother Pharmacol"},{"key":"1091_CR14","doi-asserted-by":"publisher","first-page":"4622","DOI":"10.1002\/cam4.3113","volume":"9","author":"N Shaverdian","year":"2020","unstructured":"Shaverdian N, Thor M, Shepherd AF, Offin MD, Jackson A, Wu AJ, Gelblum DY, Yorke ED, Simone CB, Chaft JE et al (2020) Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab. Cancer Med 9:4622\u20134631. https:\/\/doi.org\/10.1002\/cam4.3113","journal-title":"Cancer Med"},{"key":"1091_CR15","doi-asserted-by":"publisher","first-page":"S370","DOI":"10.1016\/j.jtho.2018.08.350","volume":"13","author":"J Vansteenkiste","year":"2018","unstructured":"Vansteenkiste J, Naidoo J, Faivre-Finn C, \u00d6zg\u00fcro\u011flu M, Villegas A, Daniel D, Murakami S, Hui R, Lee K, Cho BC, Kubota K, Poole L, Wadsworth C, Dennis P, Antonia S (2018) MA05.02 PACIFIC Subgroup Analysis: Pneumonitis in Stage III, Unresectable NSCLC Patients Treated with Durvalumab vs. Placebo After CRT. J Thorac Oncol 13:S370\u2013S371. https:\/\/doi.org\/10.1016\/j.jtho.2018.08.350","journal-title":"J Thorac Oncol"},{"key":"1091_CR16","doi-asserted-by":"publisher","first-page":"v592","DOI":"10.1093\/annonc\/mdz259.002","volume":"30","author":"JF Vansteenkiste","year":"2019","unstructured":"Vansteenkiste JF, Naidoo J, Faivre-Finn C, \u00d6zg\u00fcro\u011flu M, Villegas A, Daniel D, Murakami S, Hui R, Lee KH, Cho BC, Kubota K, Taboada M, Wadsworth C, Dennis PA, Antonia SJ (2019) Efficacy of durvalumab in patients with stage III NSCLC who experience pneumonitis (PACIFIC). Ann Oncol 30:v592\u2013v593. https:\/\/doi.org\/10.1093\/annonc\/mdz259.002","journal-title":"Ann Oncol"},{"key":"1091_CR17","doi-asserted-by":"publisher","first-page":"175883592092784","DOI":"10.1177\/1758835920927841","volume":"12","author":"T Yamada","year":"2020","unstructured":"Yamada T, Uchino J, Chihara Y, Shimamoto T, Iwasaku M, Tamiya N, Kaneko Y, Kiyomi F, Takayama K (2020) Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study). Ther Adv Med Oncol 12:1758835920927841. https:\/\/doi.org\/10.1177\/1758835920927841","journal-title":"Ther Adv Med Oncol"},{"key":"1091_CR18","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.radonc.2019.11.015","volume":"144","author":"N Shaverdian","year":"2020","unstructured":"Shaverdian N, Offin MD, Rimner A, Shepherd AF, Wu AJ, Rudin CM, Hellmann MD, Chaft JE, Gomez DR (2020) Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancer. Radiother Oncol 144:101\u2013104. https:\/\/doi.org\/10.1016\/j.radonc.2019.11.015","journal-title":"Radiother Oncol"},{"key":"1091_CR19","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.resinv.2019.03.011","volume":"57","author":"T Sakaguchi","year":"2019","unstructured":"Sakaguchi T, Ito K, Furuhashi K, Nakamura Y, Suzuki Y, Nishii Y, Taguchi O, Hataji O (2019) Patients with unresectable stage III non-small cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study criteria. Respir Investig 57:466\u2013471. https:\/\/doi.org\/10.1016\/j.resinv.2019.03.011","journal-title":"Respir Investig"},{"key":"1091_CR20","doi-asserted-by":"publisher","unstructured":"Ohri N, Halmos B, Bodner WR, Cheng H, Garg MK, Gucalp R, Guha C (2020) Who benefits the Most from adjuvant Durvalumab after Chemoradiotherapy for non-small cell lung Cancer? An Exploratory Analysis. Pract Radiat Oncol. https:\/\/doi.org\/10.1016\/j.prro.2020.09.010","DOI":"10.1016\/j.prro.2020.09.010"},{"key":"1091_CR21","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.radonc.2020.04.047","volume":"149","author":"M Offin","year":"2020","unstructured":"Offin M, Shaverdian N, Rimner A, Lobaugh S, Shepherd AF, Simone CB, Gelblum DY, Wu AJ, Lee N, Kris MG et al (2020) Clinical outcomes, local-regional control and the role for metastasis-directed therapies in stage III non-small cell lung cancers treated with chemoradiation and durvalumab. Radiother Oncol 149:205\u2013211. https:\/\/doi.org\/10.1016\/j.radonc.2020.04.047","journal-title":"Radiother Oncol"},{"key":"1091_CR22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.lungcan.2020.05.035","volume":"146","author":"HA Jung","year":"2020","unstructured":"Jung HA, Noh JM, Sun J-M, Lee S-H, Ahn JS, Ahn M-J, Pyo H, Ahn YC, Park K (2020) Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer. Lung Cancer 146:23\u201329. https:\/\/doi.org\/10.1016\/j.lungcan.2020.05.035","journal-title":"Lung Cancer"},{"key":"1091_CR23","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1111\/1759-7714.13426","volume":"11","author":"C-H Chu","year":"2020","unstructured":"Chu C-H, Chiu T-H, Wang C-C, Chang W-C, Huang AC-C, Liu C-Y, Wang C-L, Ko H-W, Chung F-T, Hsu P-C, Guo YK, Kuo CHS, Yang CT (2020) Consolidation treatment of durvalumab after chemoradiation in real-world patients with stage III unresectable non-small cell lung cancer. Thorac Cancer 11:1541\u20131549. https:\/\/doi.org\/10.1111\/1759-7714.13426","journal-title":"Thorac Cancer"},{"key":"1091_CR24","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/1759-7714.13764","volume":"12","author":"T Abe","year":"2020","unstructured":"Abe T, Saito S, Iino M, Aoshika T, Ryuno Y, Ohta T, Igari M, Hirai R, Kumazaki Y, Miura Y, Kaira K, Kagamu H, Noda SE, Kato S (2020) Effect of durvalumab on local control after concurrent chemoradiotherapy for locally advanced non-small cell lung cancer in comparison with chemoradiotherapy alone. Thorac. Cancer 12:245\u2013250. https:\/\/doi.org\/10.1111\/1759-7714.13764","journal-title":"Thorac. Cancer"},{"key":"1091_CR25","doi-asserted-by":"publisher","first-page":"5755","DOI":"10.1200\/JCO.2008.17.7840","volume":"26","author":"N Hanna","year":"2008","unstructured":"Hanna N, Neubauer M, Yiannoutsos C, McGarry R, Arseneau J, Ansari R, Reynolds C, Govindan R, Melnyk A, Fisher W et al (2008) Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J. Clin. Oncol. 26:5755\u20135760. https:\/\/doi.org\/10.1200\/JCO.2008.17.7840","journal-title":"J. Clin. Oncol."},{"key":"1091_CR26","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1200\/JCO.2015.64.8824","volume":"34","author":"S Senan","year":"2016","unstructured":"Senan S, Brade A, Wang L-H, Vansteenkiste J, Dakhil S, Biesma B, Martinez Aguillo M, Aerts J, Govindan R, Rubio-Viqueira B, Lewanski C, Gandara D, Choy H, Mok T, Hossain A, Iscoe N, Treat J, Koustenis A, San Antonio B, Chouaki N, Vokes E (2016) PROCLAIM: randomized phase III trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung Cancer. J Clin Oncol 34:953\u2013962. https:\/\/doi.org\/10.1200\/JCO.2015.64.8824","journal-title":"J Clin Oncol"},{"key":"1091_CR27","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s00066-016-0941-8","volume":"192","author":"M Flentje","year":"2016","unstructured":"Flentje M, Huber RM, Engel-Riedel W, Andreas S, Kollmeier J, Staar S, Dickgreber N, Vaissiere N, de Almeida C, Edlich B, Fietkau R (2016) GILT--A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer. Strahlenther Onkol 192:216\u2013222. https:\/\/doi.org\/10.1007\/s00066-016-0941-8","journal-title":"Strahlenther Onkol"},{"key":"1091_CR28","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1200\/JCO.2007.14.4824","volume":"26","author":"K Kelly","year":"2008","unstructured":"Kelly K, Chansky K, Gaspar LE, Albain KS, Jett J, Ung YC, Lau DHM, Crowley JJ, Gandara DR (2008) Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 26:2450\u20132456. https:\/\/doi.org\/10.1200\/JCO.2007.14.4824","journal-title":"J Clin Oncol"},{"key":"1091_CR29","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1634\/theoncologist.11-6-655","volume":"11","author":"S Ramalingam","year":"2006","unstructured":"Ramalingam S, Sandler AB (2006) Salvage therapy for advanced non-small cell lung cancer: factors influencing treatment selection. Oncologist 11:655\u2013665. https:\/\/doi.org\/10.1634\/theoncologist.11-6-655","journal-title":"Oncologist"},{"key":"1091_CR30","doi-asserted-by":"publisher","first-page":"5077","DOI":"10.21873\/anticanres.13701","volume":"39","author":"L K\u00e4smann","year":"2019","unstructured":"K\u00e4smann L, Taugner J, Eze C, Roengvoraphoj O, Dantes M, Gennen K, Karin M, Petrukhnov O, Tufman A, Belka C et al (2019) Performance Status and Its Changes Predict Outcome for Patients With Inoperable Stage III NSCLC Undergoing Multimodal Treatment. Anticancer Res. 39:5077\u20135081. https:\/\/doi.org\/10.21873\/anticanres.13701","journal-title":"Anticancer Res."}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-021-01091-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-021-01091-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-021-01091-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T05:07:39Z","timestamp":1678511259000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-021-01091-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,11]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1091"],"URL":"https:\/\/doi.org\/10.1007\/s10637-021-01091-9","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,11]]},"assertion":[{"value":"30 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients provided signed informed consent. The study was approved by the Institutional Review Board of the University hospital of the Ludwig-Maximilians-University (approval number: 17\u2013230) and was conducted according to local and federal regulations and the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All study participants provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest. Farkhad Manapov receives an Institutional research grant for participating or running clinical studies from Astrazeneca (outside of the study mentioned in the manuscript).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}